The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk

Tools

Item Type:	Article
Title:	The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk
Creators Name:	Schuster, H.
Abstract:	The GALAXY Program is a series of clinical studies investigating the efficacy and tolerability of rosuvastatin in line with the hypothesis that the statin with the greatest efficacy for improving the atherogenic lipid profile and beneficially modifying inflammatory markers will also slow progression of atherosclerosis and improve cardiovascular outcomes. Completed studies report that rosuvastatin is more effective than comparator statins in reducing low-density lipoprotein cholesterol, improving the lipid profile and enabling patients to achieve lipid goals, including revised, more stringent goals, even in high-risk patients. Studies have also reported that rosuvastatin can arrest and even regress atherosclerosis. Ongoing outcomes studies will determine whether these beneficial effects of rosuvastatin translate into reduced morbidity and mortality.
Keywords:	Atherosclerosis, cardiovascular disease, Cholesterol, Lipid-Lowering Therapy, Rosuvastatin, Statins
Source:	Expert Review of Cardiovascular Therapy
ISSN:	1477-9072
Publisher:	Future Drugs Ltd
Volume:	5
Number:	2
Page Range:	177-193
Date:	March 2007
Official Publication:	https://doi.org/10.1586/14779072.5.2.177
PubMed:	View item in PubMed

Repository Staff Only: item control page